AI-generated summary
The authors used cell and mouse experiments to study whether photobiomodulation therapy raises platelet production in chemotherapy-induced thrombocytopenia. They report that the therapy increased liver thrombopoietin expression through a reactive oxygen species-dependent Src/ERK/STAT3 pathway, and that it prevented a severe drop in platelet counts in mice. The authors describe the therapy as promising, but the abstract does not state sample sizes or clinical testing in people.
- Who or what was studied
- Thrombocytopenic mice and hepatic cells; the abstract does not describe human participants.
- Limits stated in the abstract
- The abstract reports only mouse and cell experiments, and it does not state sample sizes, light parameters or any human data.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Reactive oxygen species, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.